Tag: TCD

17 Dec 2016

TCD MENA: The family grows

What started one year ago as a dream, became a reality on 1 December 2016 when TCD MENA opened its doors in Heliopolis, Cairo as a full service CRO, serving the Middle-East and North-Africa region.

Being part of the TCD Group (www.tcd-global.com), our reach now extends from the Southern tip of the continent, to the North and the Middle-East. In the words of Dr. Hanaa Abdel-Maguid, managing director of TCD MENA: “Having been a sponsor of clinical trials for many years, I understand the needs of sponsors in a time when there are significant economic constraints globally. Part of our mission will be to convert these sponsor needs into innovative solutions that will compliment and support R&D objectives.”

The words of Eric Hoffer ring true: “In times of change, the learners shall inherit the earth, while the learned will find themselves perfectly equipped to manage a world that no longer exist.” As a learning organisation, the TCD Group will remain responsive to global trends and changing customer needs.

01 Aug 2016

Possible advance in AIDS vaccine design

A possible advancement in AIDS Vaccine design by researchers at the International Aids Vaccine Initiative (IAVI) and The Scripps Research Institute (TSRI) has been made. The researchers managed to create artificial nanoparticles (liposomes) which are covered with protein components (trimer spikes) which extend beyond the HIV-1’s outer membrane. The virus normally uses these protein components in order to attach the human cells it will eventually infect.

Thus far the particles have only been used to prompt an immune response in mice and rabbits, with positive results. The particles trigger a specific white blood cell, B cells, which can produce neutralizing antibodies. According to laboratory tests these cells have been able to neutralize a broad spectrum of the multiple variations of the most widespread HIV type, HIV-1.

Although HIV only has about a dozen of these trimer spikes on its surface, the researchers added numerous spikes to the artificial nanoparticles. Richard Wyatt, immunology professor at IAVI’s Neutralizing Antibody Centre at TSRI, as well as the senior author of the study, explains why: “We built the nanoparticle envelope with this many spikes because we thought it would offer a real advantage to trigger a more effective immune response by offering the immune system more binding sites.”

Jidnyasa Ingale, the lead author and Research Associate at TSRI further commented: “It turns out that this was indeed the case. We’ve found that the trimer-liposomes better elicits an immune response than trimers that are not packaged on such particles. This establishes our technique as a potential first step toward a more broadly effective vaccine against HIV.”

For more information on this, please go to: http://www.iavi.org/press-releases/2016/591-new-hiv-mimicking-particles-that-trigger-immune-response-could-advance-aids-vaccine-design

11 Jul 2016

MMV and Novartis expand partnership

MMV and Novartis recently announced an expansion to their current partnership. Novartis will be taking the lead in the development of the antimalarial compound KAF156, which has scientific and financial support from MMV and Bill and Melinda Gates Foundation.

According to Joseph Jimenez, CEO of Novartis: “With a child dying from malaria every two minutes and the threat of drug resistance growing year-on-year, there is a real urgency to step up global efforts to combat this disease. Partnerships and collaborations like this one with MMV are essential for the development of next generation antimalarials and accelerating efforts to eradicate this deadly disease.”

KAF156 is one of the first antimalarial drugs to enter Phase IIb clinical development in more than 20 years, working against two parasites that are responsible for the majority of malaria deaths, Plasmodium falciparum and Plasmodium vivax. KAF156 continues in the footsteps of Novartis’s first fixed-dose Artemisinin-based Combination Therapy, Coartem®, which was launched in 1999.

Dr. David Reddy, CEO of MMV, added: “We are delighted to extend our partnership with Novartis in the development of this exciting candidate antimalarial medicine with the potential to tackle drug resistance and improve patient compliance. As such, this agreement marks an important milestone, as MMV continues its mission to discover, develop and deliver new, effective and affordable antimalarials to the patients who need them most.”

For more information on this, please go to: http://www.mmv.org/newsroom/press-releases/mmv-and-novartis-expand-partnership

22 Jun 2016

New Memorandum of Understanding between TB Alliance and the Medicines Patent Pool to Improve Access to TB Medicines in Resource-Limited Countries

TB Alliance and the Medicines Patent Pool signed a Memorandum of Understanding in April 2016, outlining a multi-faceted plan to encourage the development of affordable new TB (tuberculosis) regimens and ensure their availability in low-and-middle income countries.

TB is currently the deadliest infectious disease globally, killing one person every 20 seconds, the majority of cases being in low-resource settings. Making the pandemic worse is the growing number of patients who are co-infected with HIV, as well as the emergence of multi-drug resistant (MDR-) and extensively drug-resistant (XDR-) TB. The current TB treatment regimens are long, demanding and costly, improved, faster-acting and more affordable treatment is necessary to halt this pandemic.

According to Mel Spigelman, MD, TB Alliance’s President and Chief Executive Officer “TB Alliance is pleased to partner with the Medicines Patent Pool to accelerate R&D and ensure equitable access to new therapies. With its strong track record in negotiating voluntary licenses for HIV treatments, we believe the MPP can contribute significantly toward improving the international response to combatting TB in low- and middle-income countries.”

“The MPP is thrilled to work with TB Alliance, a leading product development partnership in TB and to benefit from its significant expertise in the area of TB drug R&D,” said Greg Perry, Executive Director of the MPP. “This MOU provides an excellent opportunity to bolster both organisations’ efforts, achieve significant global health benefits in the R&D and manufacturing of new anti-TB drugs and facilitate greater and better sharing of IP for that purpose.”

For more information on this, please go to: http://www.tballiance.org/news/tb-alliance-and-medicines-patent-pool-sign-memorandum-understanding-improve-access-tb-medicines

30 May 2016

Interview: Victor Strugo – Managing Director, Triclinium Clinical Development, South Africa

The MD of Triclinium Clinical Development discusses how South Africa’s established First and Third World research opportunities and long-established GCP culture have made it a uniquely attractive country for clinical trials; how Triclinium has grown during a challenging decade, emerging as the largest independent home-bred CRO, winning significant preferred provider agreements and competing successfully against resource-rich international companies; and how the Triclinium brand is poised to take root in new territories.

Read the full article here : http://tcd-global.kbqa.co.za/wp-content/uploads/Pharma-Boardroom-Interview-Victor-Strugy-Jan-2016.pdf